Daraxonrasib plus chemotherapy shrinks tumours in 61% of patients in early pancreatic cancer trial
Daraxonrasib plus chemotherapy shrank tumours in 60.7% of 61 patients with newly diagnosed metastatic pancreatic cancer. The early trial had no chemotherapy-only group, so it cannot show whether the combination works better.
